Dynavax reports interim data for study of SD-101 in combination Merck"s Keytruda
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Xynomic reports interim data from Phase 1b study of abexinostat w/ Keytruda
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Dynavax reports results from Phase 1b/2 study of SD-101 and Keytruda combination
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
OncoSec reports interim data from Keynote-890 study of breast cancer combination
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Dynavax reports data for Phase 1b/2 trial of SD-101 in combination with Keytruda
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Heat Biologics reports interim data from HS-110 combination trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck reports interim data from Cohort B of KEYNOTE-555 Phase 1 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Vaccinex Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Completed enrollment of the dose expansion cohort in the Phase 1b/2 CLASSICAL-Lung study in non-small cell lung cancer; primary completion expected in the second half of 2019 Presented interim data from CLASSICAL-Lung study.....»»
Dynavax presents Phase 2 data on SD-101 in combination with Keytruda
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Myovant Sciences Provides Corporate Updates and Reports Financial Results for Fourth Fiscal Quarter and Full Fiscal Year Ended March 31, 2019
-Announced positive Phase 3 results from LIBERTY 1 study evaluating relugolix combination therapy in women with uterine fibroids- -Data from four additional Phase 3 clinical studies ex.....»»
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
Updated interim data from CLASSICAL-Lung study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in.....»»
Vaccinex Reports Fourth Quarter 2018 Financial Results and Provides Corporate Update
Initial data from ongoing open label study of pepinemab (VX15/2503) in combination with avelumab in non-small cell lung cancer expected in 2Q 2019 Enroll.....»»
Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer
A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»
Dynavax to present new SD-101 in combination with Keytruda data at ASCO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck"s Keytruda shows promise for melanoma
Merck said long-term data from its cancer drug Keytruda showed promise in treating advanced melanoma patients. Fred Katayama reports......»»
Epizyme reports updated interim data from Phase 2 study of tazemetostat
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bluebird Bio reports interim data from Phase 1 HGB-206 study of LentiGlobin
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Merck Gets Priority Review for Yet Another Keytruda sBLA
Merck's (MRK) sBLA to include overall survival data from a key lung cancer study on Keytruda's label gets .....»»
Regenxbio reports interim data from Phase I/II trial of RGX-12
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase development Strong fi.....»»
Cue Biopharma announces interim clinical data on phase 1 study of CUE-101
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»